In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab). HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis (eczema) in 726 patients. Amgen reported that rocatinlimab outperformed a placebo regarding the severity and extent of the disease. Amgen stock is trading lower as the data seemed to be below expectations. Goldman Sachs notes that although the Phase 3 efficacy data for rocatinlimab is less compelling compared to Dupixent, the analyst still sees strong commercial potential for the drug (if appro…